Browsing: Semaglutide

Breakthrough Trial Suggests GLP-1 Drugs Could Slow Alzheimer’s Progression Researchers have discovered that GLP-1 drugs, like liraglutide, may slow cognitive…

A recent publication in JAMA Ophthalmology has brought to light potential risks associated with the use of semaglutide, a medication often prescribed for managing type 2 diabetes (T2D) and obesity.

The cosmetic consequences of using the diabetes medication Ozempic for off-label weight loss are becoming increasingly visible. Dubbed “Ozempic face,” this phenomenon describes the rapid ageing and sagging of facial skin seen in some users.

As the world shifts its focus from the immediate threat of the COVID-19 pandemic, another health concern, often silent but equally impactful, is gaining prominence. Non-alcoholic Fatty Liver Disease (NAFLD), recognised as the “silent epidemic,” has emerged as a significant global health issue, affecting an estimated 38% of the world’s population.

With the emergence and increasing popularity of glucagon-like peptide 1 (GLP-1) agonists for the treatment of obesity in recent years, it might be worth investigating if these agents are able to reduce the cardiovascular risks associated with overweight and obesity, especially since they have been shown to reduce risk of major adverse cardiovascular events in patients with type 2 diabetes who are at high cardiovascular risk.

The use of glucagon-like peptide-1 receptor agonists (GLP-1 RA) have increased significantly in recent years due to its marked efficacy in body weight reduction in clinical trials and most recently, due to claims by celebrities and social media personalities that they have lost weight after using Ozempic (Semaglutide). While there were earlier concerns on supply shortage due to high demand of on-label and off-label use, there has been reports of a new adverse event signal that has drawn scrutiny from health authorities in the United States (US), European union (EU) and in Asia about its possible link to suicidal episodes. 

In the realm of healthcare and wellness, advancements in medical science continually push the boundaries of what is possible in managing chronic conditions. One such breakthrough in diabetes management is Ozempic.

Semaglutide tablet (Rybelsus), the first GLP-1RA developed for oral administration, heralds a milestone for diabetes management in the 15 years…